Knight Therapeutics (04K) AI Stock Analysis

0 Followers

Knight Therapeutics

(Frankfurt:04K)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Strong revenue and EBITDA growthRapid revenue and EBITDA growth indicates that Knight is converting product launches and promoted medicines into meaningful commercial scale. Raised annual guidance reinforces the durability of current execution, while stronger earnings provide additional resources to support future launches and business development.

Negative Factors

AmBisome generic competitionGeneric entry creates a defined medium-term threat to an existing revenue and EBITDA contributor in Brazil. The expected pressure could weaken portfolio profitability and require growth from newer products to offset the loss, making execution across the pipeline important to sustaining earnings power.

Knight Therapeutics (04K) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 826.13M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): 77.6
Beta (1Y): -0.00
Revenue Growth: 30.84%
EPS Growth: ―
Country: Germany
Employees: 830
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

Knight Therapeutics Business Overview & Revenue Model

Company Description

Knight Therapeutics Inc., a specialty pharmaceutical enterprise established in Montreal, Canada in 2013, operates globally, with a strong presence across Canada and Latin America. The company's core business revolves around the development, acquisiti...

Knight Therapeutics Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:2.10%|Next Earnings Date:Mar 25, 2027

Earnings Call SentimentPositive

The call was strongly positive, supported by record nine-month results, double-digit quarterly growth, raised revenue and adjusted EBITDA guidance, expanded peak revenue potential, strong cash generation, successful product launches, and continued business development momentum. The main challenges were expected pressure on AmBisome from generic competition beginning in 2027, a decline in the promoted strategic portfolio, higher operating expenses, and pending regulatory work for certain products. Management nevertheless characterized current product performance, margins, and the longer-term outlook favorably.

Positive Updates

Record Nine-Month Revenue and Adjusted EBITDA

Knight reported record results for the first nine months of 2026, with revenue of $430 million and adjusted EBITDA of over $76 million, representing growth of 36% and 57%, respectively, compared with the same period last year. Nine-month adjusted EBITDA exceeded the adjusted EBITDA reported for all of 2025.

Negative Updates

Expected AmBisome Impact from Generic Competition

A competitor received approval in September for a generic and branded generic version of AmBisome. Knight expects these products to negatively impact AmBisome sales and adjusted EBITDA contributions in Brazil starting in 2027. There were no Brazilian Ministry of Health sales in the third quarter because the 2026 contract had been completed by the end of the second quarter. Management said generic manufacturers may be in play for the 2028 contract, although Knight expects to retain some government sales because of its consistency of supply.

Company Guidance

For fiscal 2026, Knight expects revenues between $560 million and $570 million, representing top line growth of at least 24% versus 2025, and adjusted EBITDA to be approximately 17.5% of revenues, representing EBITDA growth of at least 34% versus 2025; this guidance assumes there is no material adjustment due to hyperinflation accounting in Argentina. Knight increased peak revenue potential for its pipeline and launch pipeline products from over $200 million to over $300 million, covering more than 75 product launches, 22 of which have already been executed, with peak annual revenues expected closer to 4 to 5 years; launch pipeline products generated over $67 million in revenues over the last 12 months, or more than 22% of the new peak revenue estimate. The company expects EBITDA margins to remain consistent over the next couple years, with EBITDA margins to start accelerating two to three years out, and expects to have a really high EBITDA to cash flow conversion, although there could be lumpiness between quarters.

Knight Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:04K against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TSE:CRON	83Outperform	CAD 1.78B	21.51	5.35%	―	54.74%	60.60%
TSE:CPH	74Outperform	CAD 346.41M	8.44	22.74%	―	3.18%	140.09%
TSE:OGI	59Neutral	CAD 170.62M	1.88	21.99%	―	38.14%	2030.00%
TSE:HLS	58Neutral	CAD 128.38M	-12.04	-14.43%	―	-1.18%	42.93%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TSE:ACB	51Neutral	CAD 475.99M	-5.36	-15.33%	―	-22.16%	-30.78%

* Healthcare Sector Average

Performance Comparison

DE:04K and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:04K	Knight Therapeutics	7.30	3.50	92.11%
TSE:CPH	Cipher Pharmaceuticals Inc	13.71	0.43	3.20%
TSE:OGI	Organigram Global Inc.	1.21	-0.95	-43.98%
TSE:ACB	Aurora Cannabis (US)	7.23	1.07	17.37%
TSE:CRON	Cronos Group (US)	4.93	1.44	41.26%
TSE:HLS	Hls Therapeutics	4.19	-0.56	-11.79%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Knight Therapeutics AI Stock Analysis